word count: 229 (max 250 words) Text word count: 3971 (max 4,000 words) ABSTRACT The phosphatidylinositide-3 kinases (PI3K) and the downstream mediator AKT drive survival and proliferation of multiple myeloma (MM) cells and several AKT inhibitors are currently being tested in clinical trials for MM patients. AKT inhibition has pleiotropic effects, and the key aspects that determine therapeutic efficacy are not fully clear. Therefore, we investigated the antimyeloma mechanism(s) of AKT inhibition. Among the various downstream AKT targets are Forkhead box O (FOXO) transcription factors, and we demonstrate that they are crucial for changes in gene expression upon AKT inhibition. Based on gene expression profiling we defined an AKT-induced FOXO-dependent gene set that has prognostic significance in a large cohort of MM patients, where low FOXO activity correlates with inferior survival. We show that cell cycle exit and cell death of MM cells after AKT inhibition required FOXO. In addition, glycogen synthase kinase 3 (GSK3), a negatively regulated AKT substrate, proved to be pivotal to induce cell death and to inhibit cell cycle progression after AKT inhibition. Finally, we demonstrate that FOXO and GSK3 induced cell death by increasing the turnover of the myeloid cell leukemia 1 (MCL1) protein. In concordance, the AKT inhibitor MK2206 greatly sensitized MM cells for the MCL1 inhibitor S63845. Thus, our results indicate that FOXO and GSK3 are crucial mediators of the antimyeloma effects of AKT inhibition, and suggest combination therapies that may have therapeutic potential in MM. KEYPOINTS  FOXO transcription factors and the GSK3 kinase are pivotal tumor suppressors downstream of AKT inhibition in MM cells.
INTRODUCTION
Multiple Myeloma (MM) is a malignancy of transformed clonal plasma cells that typically reside in the bone marrow. Despite considerable improvements in the median survival due to novel treatment modalities, patients inevitably relapse and become refractory to further treatment. Further understanding of MM and plasma cell biology is urgently needed and may lead to novel therapeutic strategies 1 .
The serine/threonine kinase AKT is a central node in the PI3K/AKT/mammalian target of rapamycin (mTOR) pathway, which is active in MM due to growth factors produced by the bone marrow microenvironment, or MM cells [2] [3] [4] [5] . Furthermore, hemizygous deletions of phosphatase and tensin homolog (PTEN), a negative regulator of AKT, were reported in 5-20% of MM patients and human myeloma cell lines (HMCL) 6, 7 . AKT signaling is involved in cell proliferation, survival and metabolism 3, 8 . As such, it drives proliferation and sustains the increased energy requirement of MM cells by reprogramming various metabolic pathways 8 . Due to its crucial role in oncogenesis and cell survival, AKT is an attractive therapeutic target for various types of cancer including MM, and consequently, several clinical trials assessing the efficacy of AKT inhibitors in MM are ongoing 9 .
AKT has many substrates and pleiotropic effects in healthy and malignant cells. In addition to metabolic, translational and mitogen-activated protein kinase (MAPK) pathways 8 and differentiation [11] [12] [13] [14] [15] [16] [17] . FOXOs can be phosphorylated, acetylated and ubiquitinated by a wide range of enzymes, thereby regulating their stability, localization and activity 18 .
Different interaction partners can also influence the specificity by which FOXO targets genes, regulating their expression 19 . AKT phosphorylates GSK3 on Ser9 (beta-isoform) and Ser21 (alpha-isoform), thereby inhibiting kinase activity [20] [21] [22] . GSK3 is a major AKT target involved in the regulation of cell death by controlling BCL2-family proteins 8, [23] [24] [25] [26] .
In light of the recent interest in AKT as a therapeutic target in MM, we set out to provide key insight into the antimyeloma mechanism(s) of AKT inhibition among its various downstream pathways. Here, we demonstrate that FOXO1/3 and GSK3 are AKTrestrained tumor suppressors, and that the expression of FOXO-dependent genes has prognostic value in a cohort of MM patients. Mechanistically, we provide evidence that the activation of FOXO and GSK3 provoked cell death in a nonredundant fashion through negative regulation of MCL1, a major anti-apoptotic protein in plasma cells and MM [26] [27] [28] .
In accordance, AKT inhibition greatly sensitized MM cells for the MCL1 BH3-mimetic S63845, even in MM cells resistant to AKT inhibition alone.
Our results show that the antimyeloma effects of AKT inhibition hinges on the activation of FOXO1/3 and GSK3 and provide a clear rationale to explore combination therapies aimed at AKT and its downstream targets, such as MCL1.
MATERIALS AND METHODS

Cell culture and reagents
The human MM cell lines (HMCL) LME-1, MM1.S, XG-1, XG-3, LP-1, OPM-2, ANBL-6, UM-3, and RPMI-8226 were cultured in Iscove's modified Dulbecco's medium (IMDM;
Invitrogen Life Technologies, Carlsbad, CA) supplemented with 2 mM of L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin (Gibco, Thermo Fisher Scientific, Waltham, MA) and 10% fetal calf serum (FCS; Hyclone, GE Healthcare Life Sciences, Pittsburgh, PA).
The cell lines XG-1, XG-3 and ANBL-6 were cultured in medium supplemented with 1 ng/ml interleukin-6 (IL-6; Prospec Inc, Rehovot, Israel), which was washed out prior to experiments. HEK293T cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured in supplemented Dulbecco's modified eagle medium (DMEM; Invitrogen Life Technologies) and 10% FCS. The following small-molecule inhibitors were used: GSK2110813 (Afuresertib) (AKT inhibitor; Selleckchem, Houston, TX) MK2206 (AKT inhibitor; Selleckchem), CHIR99021 (GSK3 inhibitor, Sigma Aldrich, St. Louis, MO), AS1842856 (FOXO1 inhibitor, Merck, Darmstadt, Germany), S63845 (MCL1 inhibitor, Selleckchem), cycloheximide (Sigma Aldrich).
Constructs and retroviral/lentiviral transductions
CRISPR/Cas9 knockout (KO) HMCL clones were generated by lentiviral transduction as described previously 29 . HMCLs overexpressing MCL1 were generated by retroviral transduction using the LZRS-MCL1-IRES-GFP plasmid. A more detailed description is available in the supplemental materials and methods.
Patient samples
Primary tumor cells from MM patients (>80% plasma cells) were enriched by Ficoll-paque PLUS (GE Healthcare Life Sciences) density centrifugation. Patient material was obtained according to the ethical standards of our institutional medical ethical committee, as well as in agreement with the Helsinki Declaration of 1975, as revised in 1983. Primary MM cells were cultured overnight in IMDM + 10% FCS, supplemented with 1 ng/ml IL-6 before being used in further experiments.
Immunoblotting
Immunoblotting experiments were performed as described previously 30 . Protocols and antibodies used are available in the supplemental materials and methods, densitometry quantification of immunoblots was performed using Image J software (imagej.net) 31 .
Gene expression profiling
RNA from 2 x 10 6 cells was isolated using TRI-reagent (Sigma-Aldrich) and purified using the RNEASY mini kit (Qiagen, Hilden, Germany) using the RNA cleanup protocol supplied by the manufacturer. The RNA was analyzed using Affymetrix Human Genome U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA) and normalized using MAS5.0 (accession no. GSE120941). Gene expression data was analyzed using the R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl). Venn diagrams were prepared using BioVenn (www.biovenn.nl) 32 . Enrichment plots were generated using the Broad Institute gene set enrichment analysis (GSEA) computational method and software 33 .
Flow cytometry 7
Specific cell death was assessed by 7-aminoactinomycin-D (7-AAD; Biolegend Inc, San Diego, CA) staining and flow-cytometry and calculated as reported earlier 34 . Cell cycle analysis was performed by determining DNA content and bromodeoxyuridine (BrdU) incorporation as described previously 29 . A detailed protocol is provided in the supplemental materials and methods.
Statistics
Statistical analysis was performed using the Graphpad Prism software package (Graphpad Software, La Jolla, CA) and combination indexes were calculated using CompuSyn (ComboSyn Inc, Paramus, NJ) 35 . In case single dose drug combinations were used we calculated the expected effect of drug combinations (C) using the Bliss independence model [C=A+B-(A*B)] where A and B indicate the observed cell death at specific concentrations of the single drugs 36 .
RESULTS
Inhibition of AKT induces cell death in MM cell lines and patient samples
To investigate the effects of AKT inhibition we exposed human MM cell lines (HMCL) (n=9) to increasing concentrations of the allosteric AKT inhibitor MK2206 or the ATP competitive AKT inhibitor GSK2110183 (Afuresertib), both pan-AKT (AKT1/2/3) inhibitors that are currently being evaluated for clinical activity in MM and other cancer patients 37,38 . Both inhibitors potently induced cell death in the majority of the HMCLs. However, UM-3 and RPMI-8226 were refractory to AKT inhibitor-induced cell death ( Fig 1A) . Enriched malignant plasma cells obtained from MM patients (n=6) (Suppl Fig 1A) showed a similar response, in which MK2206 induced cell death to a variable degree in all but one patient ( Fig 1B) .
To assess the downstream effects of AKT inhibition we performed immunoblotting for several established AKT targets. In all HMCLs except RPMI-8226, MK2206 decreased phosphorylation of AKT Thr308 and Ser473, targets of protein kinase PDK1 and mTOR complex 2 (mTORC2), respectively, that regulate AKT kinase activity 8 . The phosphorylation of downstream AKT substrates, FOXO1, FOXO3, GSK3beta and the ribosomal protein S6 were clearly decreased, indicating that MK2206 effectively blocked AKT function in all HMCLs except RPMI-8226. In agreement, similar effects of AKT inhibition were observed in primary MM patient samples ( Fig 1D) .
These results confirm that FOXO and GSK3 are activated upon inhibition of AKT in the context of HMCLs and primary MM cells.
FOXO transcription factors are required for AKT inhibitor-induced cell death of MM cells
To assess whether FOXO transcription factors were required for AKT inhibitor-induced cell death in MM cells we generated several FOXO1-and FOXO3-knockout clones for LME-1 (n=2), MM1.S (n=4) and XG-3 (n=4) using CRISPR/Cas9. Loss of FOXO protein expression was confirmed by immunoblotting (Fig 2A) . The loss of FOXO had no apparent effect on MM cell survival under basal condition (data not shown). However, AKT inhibitor-induced cell death was nearly abrogated in FOXO1-deficient LME-1 cells, whereas a small but significant reduction in cell death was observed in the FOXO3deficient LME-1 cells ( Fig 2B, Suppl Fig 2A) . In contrast, MK2206-induced and GSK211083-induced cell death was almost abolished in the FOXO3-deficient MM1.S and XG-3 cell lines, while FOXO1-deficient cells remained sensitive ( Fig 2B, Suppl Fig 2A) .
Of interest, we observed a slight increase in FOXO3 protein expression in FOXO1deficient LME-1 cells, and a substantial increase in FOXO1 expression in FOXO3deficient XG-3 cells (Fig 2A) .
We confirmed the tumor suppressive function of FOXO in MM using AS1842856, a small molecule inhibitor that blocks the transcriptional activity of FOXO1 and to a far lesser extent that of FOXO3 39 . In line with results observed in the FOXO-deficient cells, AS1842856 rescued LME-1 cells after MK2206 treatment but had almost no effect on the induced cell death in MM1.S cells. In other HMCLs, AS1842856 varyingly rescued MK2206-induced cell death ( Fig 2C) . These results were confirmed in MM patient samples, where AS1842856 significantly inhibited MK2206-induced cell death in 4 out of 5 patient samples tested ( Fig 2D) . The varying degree of rescue from cell death by AS1842856 may reflect the differential dependency on FOXO1 versus FOXO3 in these patients. Similarly, AS1842856 had no additional effect on FOXO1-deficient LME-1 cells, whereas AKT inhibitor-induced cell death of MM1.S cells, which required FOXO3, was partially rescued by AS1842856 (Suppl Fig 2B) . These results clearly demonstrate that FOXO transcription factors are crucial effectors of cell death upon inhibition of AKT, and function as AKT-restrained tumor suppressors in MM.
Inhibition of AKT activates FOXO-controlled transcriptional regulation in MM cells
To determine FOXO-dependent transcriptional changes we performed gene expression profiling (GEP) of two independently established FOXO1-knockout clones from the LME-1 HMCL, and of two FOXO3-knockout clones from the MM1.S and XG-3 HMCLs, respectively. Cloned wildtype "Cas9 only" cells (WT) were used as controls. We anticipated that the three HMCLs would show considerable variance in the expression of FOXO target genes, due to the heterogeneous genetic backgrounds of these HMCLs.
However, gene set enrichment analysis (GSEA) on the combined GEP datasets clearly indicated significant enrichment of a FOXO3 target gene set in the AKT inhibitor-treated WT control clones ('WTMK'; WT clones, MK2206-treated) versus the untreated control and FOXO-knockout clones, and AKT inhibitor-treated FOXO-knockout clones ('REST') ( Fig 3A) .
Using variable cutoffs, we identified FOXO-regulated genes in MM1.S (848 up, 1541 down), XG-3 (329 up, 382 down) and LME-1 (438 up, 457 down) (Suppl Table 1 ). In agreement, k-means unsupervised learning and principal component analysis (PCA) for MM1.S and XG3 showed that the MK2206-treated control clones ('WTMK') consistently clustered together versus a cluster consisting of the untreated control and FOXO3knockout clones, and the MK2206-treated FOXO3-knockout clones ('REST'). In contrast, the MK2206-treated control and FOXO1-deficient clones clustered together versus the untreated clones in LME-1. This may reflect intrinsic differences between LME-1 versus MM1.S and XG-3, and/or may indicate that FOXO1 has a less pronounced effect on gene expression compared to FOXO3 ( Suppl Fig 2A, B) . Comparing these datasets, 23 genes were found to be consistently upregulated and 44 genes were downregulated upon AKT inhibition in a FOXO-dependent fashion (Fig 3B) , among which are the established direct FOXO targets CITED2 (found in all three HMCLs) and PIK3CA (found in LME-1 and XG-3) 40,41 (Suppl Table 1 
Inhibition of AKT induces a FOXO-dependent cell cycle arrest in HMCLs
Further inspection of the GSEA data on the combined datasets showed significant depletion of cell cycle and DNA replication/repair-associated gene sets in the MK2206-treated control clones ( Fig 4A, Supplemental Fig 4A) , indicating that activation of FOXO induced cell cycle exit. In agreement, MM patients clustered according to high FOXO activity showed a significant depletion of these gene sets (Suppl Fig 4B) .
Correspondingly, cell cycle analysis showed that MK2206 treatment resulted in a significant loss of S phase and a concomitant increase in G1 phase in 7 out of 8 HMCLs tested ( Fig 4B) , including the UM-3 HMCL that was unresponsive to AKT inhibition regarding cell death ( Fig 1A) . Cell cycle exit was dependent on FOXO1 in LME-1 and on FOXO3 in MM1.S and XG-3 ( Fig 4C) . Expression of the cyclin-dependent kinase 4 (CDK4) protein, which regulates G1 phase progression, was diminished by AKT inhibition in a dose-dependent manner in MM1.S and XG-3 control cells but not in FOXO3-deficient cells. In contrast, CDK4 remained largely unaffected in LME-1 cells. Protein expression of C-MYC was reduced in all three cell lines in a FOXO-dependent manner, which is also reflected in the GSEA analysis of the MYC targets geneset ( Fig 4A) . Furthermore, C-MYC displayed higher basal protein levels in the FOXO1-deficient LME-1 cells and
FOXO3-deficient XG-3 cells compared to control cells. Protein expression of Cyclin D2
was down modulated after AKT inhibition in a FOXO3-dependent manner in MM1.S and XG-3, but appeared to be activated in the FOXO1-deficient LME-1 cells ( Fig 4D) . Analysis of GEP data indicated that the levels of CDK4 mRNA were consistently down modulated by FOXO3-activation in MM1.S and XG-3, but not in LME-1 cells, suggesting that CDK4 
GSK3 kinase activity is involved in AKT inhibitor-induced cell death and cell cycle arrest
GSK3 is an important physiological target of AKT that is inhibited by phosphorylation ( Fig   1C, D) 20 . Activation of GSK3 downstream of AKT and PI3K inhibition has been implicated in apoptosis and cell cycle arrest 21, 43 . Correspondingly, the GSK3-specific kinase inhibitor CHIR99021 significantly diminished cell death of AKT inhibitor-treated MM cells. Inhibition of GSK3 resulted in a partial rescue of MK2206-induced cell death, ranging from a 1.4fold decrease in MM1.S cells, to a 3.4-fold decrease in LME-1 cells ( Fig 5A) . A similar range of decrease in AKT inhibitor-induced cell death was observed in primary MM patient plasma cells co-treated with CHIR99021 ( Fig 5B) . GSK3 inhibition prevented AKT inhibitor-induced cell cycle arrest in the LP-1 and LME-1 HMCLs, whereas it had a modest effect in XG-3 and MM1.S. The effects of AKT inhibitor and GSK3 inhibitor treatment in XG-1 displayed a similar trend on the cell cycle as LME-1 and LP-1 but did not reach significance ( Fig 5C) . Of note, in LME-1, LP-1 and XG-3 cells we observed a significant increase in S phase upon treatment with the GSK3 inhibitor alone, suggesting that constitutive AKT signaling in these HMCLs does not completely impede GSK3 kinase activity. The activation of FOXO1 or FOXO3 appeared not to be abrogated by GSK3 inhibition (Fig 5D) . These results indicate that GSK3 significantly contributed to the antimyeloma properties of AKT inhibition, acting in a cooperative fashion with FOXO transcription factors.
GSK3 and FOXO activation upon AKT inhibition results in decreased MCL1 expression and sensitizes HMCLs for a selective MCL1 BH3 mimetic
Previously, it was shown that AKT and GSK3 kinase activity are involved in apoptosis by regulating the protein stability of MCL1 26, 44, 45 , a BCL2-family member that is essential for the survival of non-malignant plasma cells and myeloma cells 27, 46 . These findings prompted us to investigate the effects of AKT inhibition on MCL1 protein levels in MM.
MCL1 protein expression was diminished by AKT inhibitor treatment in responsive HMCLs
(LME-1, MM1.S and XG-3), which depended on FOXO and GSK3 activity ( Fig 6A) .
Similarly, MCL1 protein expression was decreased in AKT inhibitor-treated primary MM patient plasma cells ( Fig 6B) . Cycloheximide chase experiments showed that AKT inhibitor treatment increased MCL1 protein turnover in responsive HMCLs (Fig 6C) . In contrast, BCL2 and BCL-XL protein stability remained unchanged after AKT inhibition in all tested HMCLs (Suppl Fig 6A) . In agreement, overexpression of MCL1 in LME-1, MM1.S and XG-3 prevented AKT inhibitor-induced cell death (Fig 6D, E) . The S63845 small molecule inhibits MCL1 and displays potent antimyeloma acitivity 47 . Based on our results we asked whether AKT inhibition sensitized myeloma cells for this MCL1 inhibitor.
We exposed the MK2206-responsive HMCLs LME-1, MM1.S, XG-3 and the unresponsive HMCLs UM-3 and RPMI-8226 to increasing concentrations of MK2206, S63845 and the combination of both. A clear potentiating effect on induced cell death was observed with the combination of inhibitors, even in the MK2206 unresponsive HMCLs (Fig 6F, Suppl   Fig 6B) .
In accordance with the observed results in HMCLs, the combination of AKT and MCL1
inhibitors resulted in cell death consistently higher than the predicted Bliss score in primary MM cells, indicating a potentiating effect of this drug combination ( Fig 6G) . These results reports on lymphomas and other cancer cell types [57] [58] [59] [60] . As previously shown, FOXO may cause cell cycle arrest by driving the expression of the cyclin-dependent kinase inhibitor p27(kip1) 61 , and by reducing the expression of D-type cyclins 62 . We found that AKT inhibition resulted in a FOXO-dependent down modulation of cyclin D2, CDK4 and C-MYC protein expression, whereas p27(kip1) was not affected (data not shown). In agreement, GSEA indicated that MYC target genes were significantly depleted from AKT inhibitortreated control cells ( Suppl Fig 4) . In addition, DNA repair gene expression signatures were significantly down modulated upon activation of FOXO1/3 in MM ( Suppl Fig 4) ,
DISCUSSION
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